Results 141 to 150 of about 15,178 (240)

SURFACE SUBSIDENCE ABOVE SHALLOW SANDY GROUND TUNNEL

open access: yesDoboku Gakkai Ronbunshu, 1986
Toshihisa ADACHI   +3 more
openaire   +2 more sources

A Soft Robotic Fish With a Dielectric Elastomer Actuator Body and Negative Stiffness Spine

open access: yesAdvanced Robotics Research, EarlyView.
This work introduces a bio‐mimetic soft robotic fish driven by fiber‐reinforced dielectric elastomer actuators integrated as its body. By prestretching this active skin against a flexible spine, a negative stiffness system is created, enabling large‐amplitude bending.
Markus Koenigsdorff   +4 more
wiley   +1 more source

Challenges and Future Directions in Assessing the Quality and Completeness of Advanced Materials Safety Data for Re‐Usability: A Position Paper From the Nanosafety Community

open access: yesAdvanced Sustainable Systems, EarlyView.
Nanosafety data provide a guiding example for establishing best practices in data management, aligning with FAIR principles and quality criteria. This review explores existing quality assessment approaches for reliability, relevance, and completeness, emphasizing the need for harmonization and adaptation to nanomaterials and advanced materials. The aim
Verónica I. Dumit   +43 more
wiley   +1 more source

Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione‐Mediated Stemness Maintenance

open access: yesAdvanced Science, EarlyView.
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li   +17 more
wiley   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy